Objectives: This study aims to evaluate the effect of botulin toxin A in patients with multiple sclerosis (MS) affected by spasmodic dysphonia (SD) and to show the safety and effectiveness of this treatment in long-term observation.
Materials and methods: This is a pilot study on three relapsing-remitting MS patients with SD and their response to botulin toxin A.
Results: None of the patients reported dysphagia or other adverse events. Significant improvement was observed in terms of both voice quality and laryngostroboscopy results. The treatment effect was durable for 6-8 months.
Conclusions: Botulin toxin A is a safe treatment that can be successfully used to treat SD in patients with MS. Larger studies are necessary to confirm our results.
Keywords: Botulin toxin A; Dysphonia; Multiple sclerosis; Spasmodic dysphonia; Treatment.
Copyright © 2018 The Voice Foundation. Published by Elsevier Inc. All rights reserved.